

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

CHANGE OF FINANCIAL CONTROLLER

Resignation of Financial Controller

The board (the “**Board**”) of directors (the “**Directors**”) of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”) announces that, Mr. Xiang Xianqing (“**Mr. Xiang**”) has tendered his resignation as the financial controller of the Company, with effect from August 21, 2023 due to change in personal work arrangements.

Mr. Xiang has confirmed that he has no disagreement with the Company or the Board and there is no matter in relation to his resignation which needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.

Appointment of Financial Controller

The Board is pleased to announce that Ms. Chen Juan (“**Ms. Chen**”) has been appointed as the Financial Controller of the Company with effect from August 21, 2023. The biographical details of Ms. Chen are as follows:

Ms. Chen, 48, is a seasoned financial manager with more than 20 years of financial management experience in large multinational companies. She obtained a bachelor’s degree in economics from Hubei University and received a master’s degree in accounting from Tsinghua University. She also holds a licence as a Chartered Global Management Accountant and is a member of Institute of Public Accountants. From 2012 to 2015, she served as the financial director of IBM System Technology (Shenzhen) Co., Ltd. and Lenovo System Technology (Shenzhen) Co., Ltd.; from 2016 to 2017, she served as the head of internal control of the hardware system maintenance division of IBM Greater China; from 2017 to 2022, she was the person-in-charge of SF Express Group customer settlement center; from 2022 to 2023, she was the financial controller of SF Airlines; she joined Hepalink in August 2023.

The Board of Directors would like to take this opportunity to express its heartfelt thanks to Mr. Xiang for his valuable contributions to the Company during his term of office, and welcomes Ms. Chen on her new appointment.

Announcement is hereby given.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, the PRC
August 21, 2023

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Huang Peng and Mr. Yi Ming.